Ascendis Pharma (ASND) P/S ratio
There is no P/S ratio history on record here for Ascendis Pharma (ASND). Its statements are in EUR and its shares trade in USD, so figures at past share prices are not worked out. Figures as of 18 Nov 2026, 05:00 UTC, from Yahoo Finance.
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/S ratio needs at least 3 fiscal years; none is on record here for Ascendis Pharma. Nothing is estimated to fill the gap. What is on record is in the table below.
Ascendis Pharma P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Revenue per share |
|---|---|---|---|---|
| 2025 | — | — | €11.88 | |
| 2024 | — | — | €6.28 | |
| 2023 | — | — | €4.74 | |
| 2022 | — | — | €0.91 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
P/S ratio at health care companies of similar size
| Company | P/S ratio |
|---|---|
| Revvity RVTY | 5.8× |
| Exelixis EXEL | 7.2× |
| Charles River Laboratories International CRL | 4.0× |
| Neurocrine Biosciences NBIX | 5.9× |
| ICON ICLR | 1.8× |
Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.
Ascendis Pharma, figure by figure
- Ascendis Pharma market cap
- Ascendis Pharma revenue
- Ascendis Pharma earnings
- Ascendis Pharma earnings per share (EPS)
- Ascendis Pharma P/E ratio
- Ascendis Pharma P/B ratio
- Ascendis Pharma free cash flow
- Ascendis Pharma operating margin
- Ascendis Pharma dividend
- Ascendis Pharma shares outstanding
- Ascendis Pharma total debt
- Ascendis Pharma cash on hand
- Ascendis Pharma total assets
- Ascendis Pharma return on equity (ROE)
- Ascendis Pharma return on invested capital (ROIC)
Ascendis Pharma (ASND) overview: price, valuation and scorecardAll health care companies by market value
Ascendis Pharma P/S ratio: questions and answers
How is Ascendis Pharma's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Ascendis Pharma (ASND) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ASND/ps-ratio
Underlying data: Yahoo Finance.